register

Digital & Innovation

AI algorithm determines response to antidepressant

Health Industry Hub | February 19, 2020 |

Digital Health: Researchers have developed a machine learning (ML) algorithm that uses electroencephalogram (EEG) data to predict whether a selective serotonin reuptake inhibitor (SSRI) is likely to benefit a patient.

The study included more than 300 patients with depression who were randomised to treatment with an SSRI or placebo as part of the EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) trial. Using participants’ EEG data, which measured electrical activity in the brain cortex before treatment, researchers developed a machine-learning algorithm that analysed the information.

Benefit in Depression Treatment

The algorithm, they reported, accurately predicted which patients would benefit from an SSRI within 2 months. In addition, further research suggested patients unlikely to improve with an SSRI were likely to benefit from other interventions, including psychotherapy or brain stimulation.

Researchers validated their findings in 3 additional groups of patients.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. How does your company culture measure up in the industry, according to results from employee feedback? Get the benchmark analysis by contacting us.

“This study takes previous research, showing that we can predict who benefits from an antidepressant, and actually brings it to the point of practical utility,” said Amit Etkin, MD, PhD, a psychiatry professor at Stanford University, who worked with UT Southwestern psychiatrist and EMBARC trial leader Madhukar Trivedi, MD, to develop the algorithm.

The findings advance the neurobiological understanding of antidepressant treatment through an EEG-tailored computational model and provide a clinical avenue for personalized treatment of depression.

Looking to the future, they plan to develop an artificial intelligence interface that can be widely integrated with EEG machines and to gain approval from the US Food and Drug Administration (FDA).

Register FREE to receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


News & Trends - Pharmaceuticals

Clinicians unveil Novartis and BMS practice-changing trial results

Clinicians unveil Novartis and BMS practice-changing trial results

Health Industry Hub | June 24, 2024 |

Pharma News: Australia, known for its alarming melanoma rates, witnesses one person diagnosed with the disease every 30 minutes, and […]

More


News & Trends - Pharmaceuticals

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Health Industry Hub | June 24, 2024 |

Pharma News: Heart failure is a significant health concern in Australia, affecting approximately half a million people, with over 67,000 […]

More


News & Trends - MedTech & Diagnostics

Cardiologists mark Australian first with Boston Scientific's intracoronary imaging system

Cardiologists mark Australian first with Boston Scientific’s intracoronary imaging system

Health Industry Hub | June 24, 2024 |

MedTech & Diagnostics News: Percutaneous coronary intervention (PCI) has faced substantial complications and failure rates, despite advances in medical devices […]

More


Leadership & Management

AbbVie New Zealand welcomes new leadership amid global moves

AbbVie New Zealand welcomes new leadership amid global moves

Health Industry Hub | June 24, 2024 |

Leadership & Management: In line with its global talent development plan, AbbVie has announced a significant change in leadership for […]

More


This content is copyright protected. Please subscribe to gain access.